Loading...
  • Therapeutics
  • PHILADELPHIA and OXFORD, United Kingdom, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in the use of TCR engineered T-cell therapy to treat cancer, and Seattle-based Universal Cells Inc., a genome editing company developing universal donor stem cells, today announced that they have entered into a collaboration and exclusive license agreement for the development of allogeneic T-cell therapies. (cnbc.com)
  • Adaptimmune and Universal Cells are planning to develop these off-the-shelf allogeneic affinity-enhanced T-cell therapeutics to treat large patient populations. (cnbc.com)
  • leukemia
  • Alemtuzumab is a drug that is designed to specifically attack some types of leukemia and lymphoma cells. (knowcancer.com)
  • Mechanisms of immune evasion can involve abrogation of leukemia cell recognition due to the loss of HLA genes, immunosuppression by immune checkpoint ligand expression, production of anti-inflammatory factors, release of metabolically active enzymes, loss of pro-inflammatory cytokine production and acquisition of novel driver mutations that promote leukemia outgrowth. (bloodjournal.org)
  • The rationale behind the NST strategy is to induce optimal graft-versus-leukemia (GVL) effects for the elimination of all malignant cells by alloreactive immunocompetent cells from a matched donor as an alternative to standard high-dose myeloablative chemo radiotherapy. (clinicaltrials.gov)
  • therapeutic
  • Intratumoral administration of an immune primer is a therapeutic vaccine strategy aimed to trigger dendritic cell (DC)-mediated cross-presentation of cell-associated tumor antigens to cytotoxic CD8 + T cells without the need for tumor antigen characterization. (springer.com)
  • Agents known as immune check point inhibitors (CPIs), particularly therapeutic antibodies that block the immunosuppressive programmed cell death protein-1 (PD-1) and the programmed cell death-ligand 1 (PD-L1) pathway, are now revolutionizing the practice of medical oncology due to their ability to improve outcomes in various malignancies. (springer.com)
  • This partnership will combine Universal Cells' nuclease-free genome editing platform with Adaptimmune's unique expertise in TCR engineering to develop a first-in-class therapeutic product based on our universal donor cells. (cnbc.com)
  • They are able to generate cell lines derived from any of the three embryonic germ layers (ectoderm, mesoderm and endoderm), giving them great therapeutic potential. (intechopen.com)
  • However, based on the so‚Äźcalled phenomenon of cellular plasticity, in some instances, they can differentiate into cell populations different to those of their embryonic origin, providing many therapeutic options [ 16 ]. (intechopen.com)
  • tumor
  • The mechanism of action of ilixadencel is to induce recruitment and activation of endogenous immune cells, including NK cells that subsequently promotes cross-presentation of cell-associated tumor antigens by co-recruited DCs. (springer.com)
  • In most mouse models, anti-tumor immunity requires the generation of tumor-specific cytotoxic CD8 + T cells (CTLs) and it is similarly believed that CTLs are major players in successful immunotherapies of human cancers. (springer.com)
  • Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis. (semanticscholar.org)
  • genetically
  • The implantation of genetically engineered cells is an attractive strategy for the chronic long-term delivery of recombinant proteins. (epfl.ch)
  • Therefore, this encapsulation system is an effective platform for the implantation of genetically engineered cells in allogeneic conditions, which could be adapted to the chronic administration of recombinant proteins. (epfl.ch)
  • A procedure in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical, donor. (cancer.gov)
  • Cyclophosphamide
  • Cyclophosphamide is designed to interfere with the multiplication of cancer cells, which may slow or stop their growth and spread throughout the body. (knowcancer.com)
  • Phase
  • Allogeneic SCT was performed from his full-matched male donor during the accelerated phase. (hindawi.com)
  • Its NY-ESO TCR affinity enhanced T-cell therapy has demonstrated signs of efficacy and tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer types, including synovial sarcoma and multiple myeloma. (cnbc.com)
  • subcutaneous
  • In order to quantitate the number of cells surviving in the device and optimize initial conditions leading to high-density survival, we implant devices containing C2C12 mouse myoblasts expressing a luciferase reporter in the mouse subcutaneous tissue. (epfl.ch)
  • adoptive
  • Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy. (semanticscholar.org)
  • immunotherapy
  • By partnering with the world leader in TCR engineered T-cell immunotherapies, we are poised to develop a scalable, safe, and efficacious product with the potential to revolutionize cancer immunotherapy," said Claudia Mitchell, Chief Executive Officer of Universal Cells. (cnbc.com)
  • Under the terms of the agreement, Universal Cells will grant to Adaptimmune an exclusive, sub-licensable, worldwide license to use, sell, supply, manufacture, import, and develop products and services utilizing Universal Cells' technology within the T-cell immunotherapy field. (cnbc.com)
  • Adaptimmune is a clinical stage biopharmaceutical company focused on novel cancer immunotherapy products based on its T-cell receptor (TCR) platform. (cnbc.com)
  • BACKGROUND Renal cell cancer and malignant melanoma are two types of cancer that are responsive to immunotherapy. (semanticscholar.org)
  • Challenges of NK cell-based immunotherapy in the new era. (semanticscholar.org)
  • Treatment
  • It is as a result of these inadequacies in current treatment strategies that cell therapy has arisen as a complementary option [ 14 ]. (intechopen.com)
  • therapy
  • The main risk factor for HAdV infection is prolonged immunosuppression, attributable either to in vivo or ex vivo T-cell depletion, prolonged lymphopenia, or to GvHD-associated immunosuppressive posttransplant therapy. (springer.com)
  • Adaptimmune's lead program is an affinity enhanced T-cell therapy targeting the NY-ESO cancer antigen. (cnbc.com)
  • In addition, Adaptimmune has a number of proprietary programs and its next affinity enhanced T-cell therapy, directed at MAGE A-10, is scheduled to enter the clinic shortly. (cnbc.com)
  • Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes. (semanticscholar.org)
  • In this scenario, cell therapy is envisaged as an effective alternative to surgery. (intechopen.com)
  • The promising preclinical and clinical data that we review below suggest that cell therapy could represent a major advance in the clinical management of this difficult problem. (intechopen.com)